Celcuity Inc. (CELC) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
the bull case· 3
279
managers reporting positions in thirteen f filings
13fJun 30 '2633
managers whose positions comprise four fifths of reported value
13fJun 30 '26+5.71%
change in shares held by the ten largest reporting managers
13fJun 30 '26the bear case· 3
4
funds on file reporting a position in CELC
n-portas of Jun 30 '261.10%
State Street SPDR S and P Biotech ETF share of assets, largest fund weight
n-portJun 30 '265 of 24
largest reporting managers who cut their stake in the latest quarter
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 12 '26 report. Not a forecast, not advice.
Of the 2 companies Celcuity Inc. moves with most closely, none share its SEC classification.
Measured against 149 trading days of our own closes. Co-movement, not cause.
SIC 8071, Services-Medical Laboratories, from each company's own filings. Largest first.
278 managers report a position worth $6.1B between them, and 33 of them hold 80% of it.
Celcuity Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Services-Medical Laboratories
High 85.94 at 6:15 am ET, low 80.51 at 4:00 pm ET.
tall tick = annual report · 1 on record
CELC (Celcuity Inc.) has 0 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.